- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05686226
E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers
October 10, 2023 updated by: Christian Hinrichs
A Phase II Trial of T Cell Receptor Gene Therapy Targeting Human Papillomavirus ( HPV) 16 E7 for HPV-Associated Cancers
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers.
HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other cancers.
Participants will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin.
Clinical response to treatment will be determined.
Study Overview
Status
Recruiting
Conditions
- Cervical Cancer
- HPV-Related Malignancy
- Metastatic Cancer
- Anal Cancer
- Oropharynx Cancer
- Vaginal Cancer
- HPV-Related Carcinoma
- HPV-Related Cervical Carcinoma
- HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Penile Cancer
- HPV-Related Adenocarcinoma
- HPV-Related Adenosquamous Carcinoma
- HPV-Related Squamous Cell Carcinoma
- HPV-Related Anal Squamous Cell Carcinoma
- HPV-Related Penile Squamous Cell Carcinoma
- HPV-Related Vulvar Squamous Cell Carcinoma
- HPV-Related Endocervical Adenocarcinoma
- Throat Cancer
- Vulva Cancer
- HPV-Associated Vaginal Adenocarcinoma
- HPV Positive Rectal Squamous Cell Carcinoma
Intervention / Treatment
Detailed Description
This study will determine the tumor response rate for the treatment of HPV-associated cancers with E7 TCR-T cells.
E7 TCR-T cells are autologous gene-engineered T cells that target HPV16 E7 through a T cell receptor (TCR).
E7 is an HPV oncoprotein that is present in HPV-associated cancers.
Participants must have the HLA-A*02:01 allele, which is required for tumor targeting by the E7 TCR.
Treatment consists of a conditioning regimen (cyclophosphamide and fludarabine), a single infusion of E7 TCR-T cells, and adjuvant aldesleukin.
Tumor response rate and response duration will be determined.
Safety data will also be collected.
Study Type
Interventional
Enrollment (Estimated)
20
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Carrie Snyder
- Phone Number: 732-235-7356
- Email: cs1449@cinj.rutgers.edu
Study Locations
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Recruiting
- Rutgers Cancer Institute of New Jersey
-
Contact:
- Carrie Snyder
- Phone Number: 732-235-7356
- Email: cs1449@cinj.rutgers.edu
-
New Brunswick, New Jersey, United States, 08901
- Not yet recruiting
- RWJBarnabas Health - Robert Wood Johnson University Hospital
-
Contact:
- Carrie Snyder
- Phone Number: 732-235-7356
- Email: cs1449@cinj.rutgers.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically or cytologically confirmed metastatic or refractory/recurrent HPV-16+ cancer.
- Tumor with HPV16 genotype as determined by testing performed in a CLIA certified laboratory.
- HLA-A*02:01 allele as determined by testing performed in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory. Participants may be enrolled based on low resolution typing (i.e., HLA-A*02) but the HLA-A*02:01 allele type must be confirmed prior to apheresis.
- Measurable disease as assessed by RECIST Criteria Version 1.114.
- Age ≥ 18 years.
- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 at screening.
- Must have received prior first line standard therapy or have declined standard therapy.
- Standard treatment options for first and second-line therapy must be presented and formally declined (Appendix VII).
- Patients with three or fewer brain metastases that have been treated with surgery or stereotactic radiosurgery are eligible. Lesions that have been treated with stereotactic radiosurgery must be clinically stable for one month before protocol treatment. Patients must be fully recovered from surgery.
- Negative pregnancy test for women under 55 and all women who have had a menstrual period in the last 12 months. A pregnancy tests is not required for women who have had a bilateral oophorectomy or hysterectomy.
- Men and women of child-bearing potential must agree to use adequate contraception (i.e., intrauterine device, hormonal barrier method of birth control; abstinence; tubal ligation or vasectomy) prior to study entry and for four months after treatment. Should a women become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately.
- Seronegative for HIV antibody, hepatitis B antigen, and hepatitis C antibody. If a hepatitis C antibody test is positive, then testing for antigen by RT-PCR for Hepatitis C (HCV) RNA must be negative.
Participants must have organ and marrow function as defined below:
- Leukocytes > 3,000/microliter (mcL)
- Absolute neutrophil count > 1,500/mcL
- Platelets > 100,000/mcL
- Hemoglobin > 8.0 g/dL
- Total bilirubin within normal institutional limits except in participants with Gilbert's Syndrome who must have a total bilirubin < 3.0 mg/dL.
- Serum aspartate transferase (AST) (SGOT)/alanine transaminase (ALT) (SGPT) < 2.5 x upper limit of normal (ULN)
- Calculated creatinine clearance (CrCl) >50 mL/min/1.73 m2for participants with creatinine levels above institutional normal (by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation).
- international normalized ratio (INR) or activated partial thromboplastin time ( aPTT) ≤1.5 X ULN unless the subject is receiving anticoagulant therapy. Subjects on anticoagulant therapy must have a PT or aPTT within therapeutic range and no history of severe hemorrhage.
- More than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the E7 TCR cells.
- Participants must be able to understand and be willing to sign the written informed consent document.
- Participants must agree to participate in protocol Cancer Institute of New Jersey (CINJ) 192103 (Pro2021002307) for gene therapy long term follow up and in protocol CINJ 192002 (Pro2021000281) for biospecimen collection study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: E7 TCR-T cells
Subjects will receive a conditioning regimen, E7 TCR-T cells, and aldesleukin.
|
Participants will receive a conditioning regimen (cyclophosphamide and fludarabine), E7 TCR-T cells as a single infusion, and adjuvant high-dose aldesleukin.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor response
Time Frame: Five years
|
Objective tumor response as measured by RECIST
|
Five years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: 5 years
|
Adverse events as measured by CTCAE
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Christian Hinrichs, MD, Rutgers Cancer Institute of New Jersey
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 7, 2023
Primary Completion (Estimated)
January 1, 2025
Study Completion (Estimated)
January 1, 2025
Study Registration Dates
First Submitted
December 25, 2022
First Submitted That Met QC Criteria
January 8, 2023
First Posted (Actual)
January 17, 2023
Study Record Updates
Last Update Posted (Actual)
October 12, 2023
Last Update Submitted That Met QC Criteria
October 10, 2023
Last Verified
October 1, 2023
More Information
Terms related to this study
Keywords
- immunotherapy
- gene therapy
- cell therapy
- TCR
- cellular therapy
- HPV
- cervical cancer
- T cell
- human papillomavirus
- anal cancer
- oropharyngeal cancer
- Tumor infiltrating lymphocyte
- TCR-T
- vaginal cancer
- vulvar cancer
- lymphocyte
- adoptive cell therapy
- T cell receptor
- penile cancer
- Chimeric antigen receptors (CAR-T)
- E7
- E7 TCR
- tumor infiltrating lymphocytes (TIL)
- TIL therapy
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Genital Neoplasms, Male
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Neoplasms, Complex and Mixed
- Vaginal Diseases
- Neoplasms, Squamous Cell
- Vulvar Diseases
- Rectal Neoplasms
- Anus Diseases
- Penile Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Genital Diseases, Female
- Uterine Cervical Neoplasms
- Carcinoma
- Adenocarcinoma
- Carcinoma, Squamous Cell
- Squamous Cell Carcinoma of Head and Neck
- Vulvar Neoplasms
- Carcinoma, Adenosquamous
- Anus Neoplasms
- Oropharyngeal Neoplasms
- Vaginal Neoplasms
- Penile Neoplasms
Other Study ID Numbers
- 192204
- Pro2022002259 (Other Identifier: Rutgers, The State University of New Jersey)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Primary and secondary endpoint data will be shared.
IPD Sharing Time Frame
Data will be made available through the publisher at the time of publication.
IPD Sharing Access Criteria
Data will be accessible through the publisher.
IPD Sharing Supporting Information Type
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Cancer
-
University of California, San DiegoWithdrawnCervical Cancer | Cervical Cancer Stage | Cervical Cancer Stage IB2 | Cervical Cancer Stage IB1 | Cervical Cancer Stage I | Cervical Cancer Stage IB | Cervical Cancer Stage II | Cervical Cancer Stage IIa | Cervical Cancer, Stage IIB | Cervical Cancer, Stage III | Cervical Cancer Stage IIIB | Cervical Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterWithdrawnStage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical Cancer FIGO 2018 | Stage IIB Cervical Cancer FIGO 2018 | Stage III Cervical Cancer FIGO 2018 | Stage IIIA Cervical Cancer FIGO... and other conditions
-
Abramson Cancer Center of the University of PennsylvaniaWithdrawnCervical Cancer | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IA Cervical Cancer | Stage IB Cervical Cancer | Stage IA1 Cervical Cancer | Stage IA2 Cervical Cancer | Stage IB1 Cervical Cancer | Stage IB2 Cervical Cancer | Stage IB3 Cervical CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingCervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma, Not Otherwise Specified | Recurrent Cervical Carcinoma | Stage IB3 Cervical Cancer FIGO 2018 | Stage II Cervical Cancer FIGO 2018 | Stage IIA Cervical Cancer FIGO 2018 | Stage IIA1 Cervical Cancer FIGO 2018 | Stage IIA2 Cervical... and other conditionsUnited States
-
Shanghai First Maternity and Infant HospitalNot yet recruitingCervical Cancer, Stage IIB | Cervical Cancer Stage IIIB | Cervical Cancer Stage IIIA | Cervical Cancer, Stage IVA
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical Cancer | Stage IIIA Cervical Cancer | Stage IIIB Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance
Clinical Trials on E7 TCR-T cells
-
Christian HinrichsNational Cancer Institute (NCI)Not yet recruitingCervical Cancer | HPV-Related Malignancy | Vulvar Cancer | Anal Cancer | Oropharynx Cancer | Vaginal Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Penile Cancer | HPV-Associated Cervical Carcinoma | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma | HPV-Related... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedImmunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial LesionsNeoplasms, Squamous Cell | Squamous Lntraepithelial Lesions of Vulva | Vulvar HSILUnited States
-
National Cancer Institute (NCI)WithdrawnPapillomavirus Infections | Oropharyngeal NeoplasmsUnited States
-
Sun Yat-sen UniversityUnknownNasopharyngeal CarcinomaChina
-
Second Affiliated Hospital of Guangzhou Medical...Tcell Immune (Guangzhou) Science and Technology Ltd.RecruitingNonsmall Cell Lung Cancer | Solid Tumor, AdultChina
-
National Cancer Institute (NCI)WithdrawnCervical Intraepithelial NeoplasiaUnited States
-
Beijing 302 HospitalLion TCR Pte. Ltd.Recruiting
-
Hebei Yanda Ludaopei HospitalChina Immunotech (Beijing) Biotechnology Co., Ltd.CompletedCMV Infection or Reactivation After Allogenic HSCTChina
-
Chinese PLA General HospitalRecruitingEBV Infection | EBV-associated Hemophagocytic LymphohistiocytosisChina
-
Xiao-Jun HuangRecruitingAllogeneic Hematopoietic Stem Cell Transplantation | CMV InfectionChina